In April 2016 Manchester eScholar was replaced by the University of Manchester’s new Research Information Management System, Pure. In the autumn the University’s research outputs will be available to search and browse via a new Research Portal. Until then the University’s full publication record can be accessed via a temporary portal and the old eScholar content is available to search and browse via this archive.

Related resources

Full-text held externally

University researcher(s)

    Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis.

    Kong, Anthony; Johnson, Nick; Kitchener, Henry C; Lawrie, Theresa A

    Journal of the National Cancer Institute. 2012;104(21):1625-34.

    Access to files

    Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:

    Full-text held externally

    Abstract

    BACKGROUND: The role of adjuvant radiotherapy in stage I endometrial cancer has changed in recent years. This updated Cochrane systematic review aimed to reexamine the efficacy and toxicity of adjuvant radiotherapy vs no treatment in stage I endometrial cancer. METHODS: We searched various databases including The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and the Specialised Register of the Cochrane Gynaecological Cancer Review Group (CGCRG) for randomized controlled trials that met the predefined inclusion criteria. The primary outcome was overall survival (OS); secondary outcomes were endometrial cancer-specific survival, locoregional recurrence, distant recurrence, and toxicity. Hazard ratios (HRs) were estimated and pooled if possible; otherwise, dichotomous data were extracted. All statistical tests were two-sided. RESULTS: Of the eight included trials, seven trials (3628 women) compared external beam radiotherapy (EBRT) and no EBRT (or vaginal brachytherapy [VBT]), and one trial (645 women) compared VBT and no additional treatment. EBRT statistically significantly reduced locoregional recurrence compared with no EBRT (or VBT alone) (HR = 0.36, 95% confidence Interval [CI] = 0.25 to 0.52; P < .001), but this did not translate into an improvement in OS (HR = 0.99, 95% CI = 0.82 to 1.20; P = .95), endometrial cancer-specific survival (HR = 0.96, 95% CI = 0.72 to 1.28; P = .80), or distant recurrence rates (risk ratio = 1.04, 95% CI = 0.80 to 1.35; P = .77). EBRT was associated with an increased risk of severe acute toxicity, severe late toxicity, and reduced quality of life scores. CONCLUSIONS: EBRT reduces the risk of locoregional recurrence but has no statistically significant impact on cancer-related deaths or OS. However, EBRT is associated with clinically and statistically significant morbidity and a reduction in quality of life.

    Bibliographic metadata

    Type of resource:
    Content type:
    Publication type:
    Published date:
    Abbreviated journal title:
    ISSN:
    Place of publication:
    United States
    Volume:
    104
    Issue:
    21
    Pagination:
    1625-34
    Digital Object Identifier:
    10.1093/jnci/djs374
    Pubmed Identifier:
    22962693
    Pii Identifier:
    djs374
    Access state:
    Active

    Institutional metadata

    University researcher(s):
    Academic department(s):

    Record metadata

    Manchester eScholar ID:
    uk-ac-man-scw:197282
    Created by:
    Kitchener, Henry
    Created:
    10th June, 2013, 09:20:06
    Last modified by:
    Kitchener, Henry
    Last modified:
    11th April, 2016, 09:05:42

    Can we help?

    The library chat service will be available from 11am-3pm Monday to Friday (excluding Bank Holidays). You can also email your enquiry to us.